Business
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
BOSTON, December 08, 2025--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/0988ca56ef003058f5b98e3008cb8134"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/J15gwHwBUEUop79WDlQ1uA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0988ca56ef003058f5b98e3008cb8134","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/5CZnOdI_8l3xvXKVPannig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/0988ca56ef003058f5b98e3008cb8134","width":1200,"height":385}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":250,"url":"https://media.zenfs.com/en/business-wire.com/0485fc0b349fd2cfc8a63db017bce98f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IUKKyegHMV6Z.ewLMyC3rA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0485fc0b349fd2cfc8a63db017bce98f","width":480,"height":250}}},{"type":"text","content":"Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway","length":138,"tagName":"p","attribs":{}},{"type":"text","content":"Phase 3 SURPASS-IPF trial remains on track to be initiated by PureTech’s Founded Entity, Celea Therapeutics, in the first half of 2026","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, December 08, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced the successful completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF). Deupirfenidone is being advanced by Celea Therapeutics, a Founded Entity established by PureTech to lead its late-stage development and potential commercialization.","length":661,"tagName":"p"},{"type":"text","content":""...